Board of Directors
Chief Executive Officer
Joshua joined Cytel in January 2019. He is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. Prior to joining Cytel he served as an Officer of PAREXEL and Senior Vice President for PAREXEL’s Access business unit. Joshua holds a B.S.E. in Finance from the Wharton School of Business, a B.A. in International Relations from the University of Pennsylvania, and Master of Philosophy in International Relations from the University of Cambridge, UK.
Partner, Nordic Capital Advisors
Daniel joined Nordic Capital in January 2010. He has served on the boards of nine Nordic Capital portfolio companies. Daniel focuses on investment situations within Technology and Payments as well as Healthcare IT. Before joining Nordic Capital, he worked at Bain & CO (2007–2009) as Senior Associate. Daniel holds an MSc in Economics and Business Administration from the Stockholm School of Economics and the Ross School of Business at the University of Michigan.
Partner & Head of Healthcare, Astorg
Judith joined Astorg in 2009. She leads the Healthcare franchise globally at Astorg and serves on the board of several healthcare companies. Before joining Astorg, she worked at Fondations Capital and Morgan Stanley. Judith is an ESSEC graduate and holds a Masters in Political Science from Paris I Panthéon-Sorbonne University.
Christopher joined Astorg in 2020. He worked at Bain Capital in New York and London from 2011 to 2020. Prior to this, he worked at Bain and Company in San Francisco and Dubai, and at Cinven in Paris. Christopher holds an MSc in Engineering from Mines ParisTech, an MSc in finance from Paris Sorbonne and an MBA from the Stanford Graduate School of Business.
Principal, Nordic Capital Advisors
Joel joined Nordic Capital in March 2012. He worked in the Investment Banking Division at Goldman Sachs in London from 2010 to February 2012. Joel has an MSc in Finance from Helsinki School of Economics.
Managing Director, Blackstone Life Sciences Group
Barry joined Blackstone as part of its acquisition of Clarus Funds. He brings 28 years of experience in drug development, from exploratory clinical pharmacology to global Phase 3 trials. This includes development of blockbuster products like Fosamax, Januvia and Keytruda. He is currently a member of the External Advisory Board for the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania School of Medicine. Before joining Clarus, Dr. Gertz was Senior Vice President and Head of Global Clinical Development at Merck. He received an MD, PhD in Pharmacology and a BA from the University of Pennsylvania.
Olivier joined Astorg in 2015. He worked at Barclays and 3i in Paris from 2012 to 2015. Olivier is a graduate civil engineer from Ecole Polytechnique and Ecole Nationale des Ponts et Chaussées in Paris, and holds a Master of Science in Economics from the Paris School of Economics.
Director, Nordic Capital Advisors
Tom joined Nordic Capital in March 2014. He worked in the Investment Banking Division at Rothschild in London from 2010 to 2014. Tom holds a BSc in Economics and Business Administration from the Stockholm School of Economics.